ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34+ CD38- population to imatinib

Experimental Hematology

Volumn 40, Issue 5, 2012, Pages

  Airiau, Kelly ^a,b   Mahon, François Xavier ^a,b   Josselin, Marina ^a   Jeanneteau, Marie ^b   Turcq, Beatrice ^a   Belloc, Francis ^a,b  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE 3; CD34 ANTIGEN; CD38 ANTIGEN; IMATINIB; NILOTINIB; PROTEIN BCL 2; SERINE PROTEINASE OMI; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CELL POPULATION; CHEMOSENSITIZATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PROCESSING;

EID: 84859726070     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.01.004     Document Type: Article

References (39)

1. Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005, 5:172-183.
2. Goldman J.M. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007, 110:2828-2837.
3. Breccia M., Efficace F., Alimena G. Imatinib treatment in chronic myelogenous leukemia: what have we learned so far?. Cancer Lett 2011, 300:115-121.
4. Corbin A.S., Agarwal A., Loriaux M., Cortes J., Deininger M.W., Druker B.J. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest 2011, 121:396-409.
5. van Delft M.F., Huang D.C. How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Res 2006, 16:203-213.
6. Antignani A., Youle R.J. How do Bax and Bak lead to permeabilization of the outer mitochondrial membrane?. Curr Opin Cell Biol 2006, 18:685-689.
7. Steelman L.S., Abrams S.L., Whelan J., et al. Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia 2008, 22:686-707.
8. Belloc F., Moreau-Gaudry F., Uhalde M., et al. Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines. Cancer Biol Ther 2007, 6:912-919.
9. Vogler M., Weber K., Dinsdale D., et al. Different forms of cell death induced by putative BCL2 inhibitors. Cell Death Differ 2009, 16:1030-1039.
10. Vogler M., Dinsdale D., Sun X.M., et al. A novel paradigm for rapid ABT-737-induced apoptosis involving outer mitochondrial membrane rupture in primary leukemia and lymphoma cells. Cell Death Differ 2008, 15:820-830.
11. Kline M.P., Rajkumar S.V., Timm M.M., et al. ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis in multiple myeloma cells. Leukemia 2007, 21:1549-1560.
12. Kuroda J., Kimura S., Andreeff M., et al. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. Br J Haematol 2008, 140:181-190.
13. Kuroda J., Puthalakath H., Cragg M.S., et al. Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci U S A 2006, 103:14907-14912.
14. Salvesen G.S., Duckett C.S. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol 2002, 3:401-410.
15. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009, 23:467-476.
16. Weisberg E., Ray A., Barrett R., et al. Smac mimetics: implications for enhancement of targeted therapies in leukemia. Leukemia 2010, 24:2100-2109.
17. Belloc F., Cotteret S., Labroille G., et al. Bcr-abl translocation can occur during the induction of multidrug resistance and confers apoptosis resistance on myeloid leukemic cell lines. Cell Death Differ 1997, 4:806-814.
18. Mahon F.X., Deininger M.W., Schultheis B., et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood 2000, 96:1070-1079.
19. Vayssiere J.L., Petit P.X., Risler Y., Mignotte B. Commitment to apoptosis is associated with changes in mitochondrial biogenesis and activity in cell lines conditionally immortalized with simian virus 40. Proc Natl Acad Sci U S A 1994, 91:11752-11756.
20. Chou T.C., Talalay P. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 1981, 115:207-216.
21. Vial J.P., Belloc F., Dumain P., et al. Study of the apoptosis induced in vitro by antitumoral drugs on leukaemic cells. Leuk Res 1997, 21:163-172.
22. Real P.J., Sierra A., De Juan A., Segovia J.C., Lopez-Vega J.M., Fernandez-Luna J.L. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002, 21:7611-7618.
23. Wesarg E., Hoffarth S., Wiewrodt R., et al. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer. Int J Cancer 2007, 121:2387-2394.
24. Walsh J.G., Cullen S.P., Sheridan C., Luthi A.U., Gerner C., Martin S.J. Executioner caspase-3 and caspase-7 are functionally distinct proteases. Proc Natl Acad Sci U S A 2008, 105:12815-12819.
25. Vaux D.L., Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003, 304:499-504.
26. Suzuki Y., Takahashi-Niki K., Akagi T., Hashikawa T., Takahashi R. Mitochondrial protease Omi/HtrA2 enhances caspase activation through multiple pathways. Cell Death Differ 2004, 11:208-216.
27. Cilenti L., Lee Y., Hess S., et al. Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. J Biol Chem 2003, 278:11489-11494.
28. Kuroda J., Kimura S., Strasser A., et al. Apoptosis-based dual molecular targeting by INNO-406, a second-generation Bcr-Abl inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against Bcr-Abl-positive leukemia. Cell Death Differ 2007, 14:1667-1677.
29. Pocaly M., Lagarde V., Etienne G., et al. Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 2007, 21:93-101.
30. Fang G., Kim C.N., Perkins C.L., et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000, 96:2246-2253.
31. Cascio C., Guarneri R., Russo D., et al. A caspase-3-dependent pathway is predominantly activated by the excitotoxin pregnenolone sulfate and requires early and late cytochrome c release and cell-specific caspase-2 activation in the retinal cell death. J Neurochem 2002, 83:1358-1371.
32. Dussmann H., Rehm M., Kogel D., Prehn J.H. Outer mitochondrial membrane permeabilization during apoptosis triggers caspase-independent mitochondrial and caspase-dependent plasma membrane potential depolarization: a single-cell analysis. J Cell Sci 2003, 116:525-536.
33. Belizario J.E., Alves J., Occhiucci J.M., Garay-Malpartida M., Sesso A. A mechanistic view of mitochondrial death decision pores. Braz J Med Biol Res 2007, 40:1011-1024.
34. Mak D.H., Wang R.Y., Schober W.D., et al. Activation of apoptosis signaling eliminates CD34(+) progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia 2011 Oct 28, [Epub ahead of print]. 10.1038/leu.2011.285.
35. Zhang J., Li Y., Shen B. Up-regulation of XIAP by M-CSF is associated with resistance of myeloid leukemia cells to apoptosis. Leukemia 2002, 16:2163-2165.
36. Belloc F., Airiau K., Jeanneteau M., et al. The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells. Leukemia 2009, 23:679-685.
37. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
38. Costa D.B., Halmos B., Kumar A., et al. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007, 4:1669-1679. discussion 1680.
39. Mason K.D., Carpinelli M.R., Fletcher J.I., et al. Programmed anuclear cell death delimits platelet life span. Cell 2007, 128:1173-1186.